UK pharma sector navigates 2025 trade, regulatory and Artificial Intelligence shifts
The UK pharmaceutical sector in 2025 faced a reshaped legal and regulatory environment spanning trade policy, life sciences strategy, clinical trials reform, competition enforcement, investment trends and emerging Artificial Intelligence regulation. New frameworks and enforcement tools are set to influence pricing, market access, corporate liability and the deployment of Artificial Intelligence in healthcare and drug discovery.